Frontiers in oncology · 2026
Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Song, Chen Ting, Yin Shunhang, Yu Guangji, Wang Qingdong, Li Long, Zhao Guangsheng, Zhang Lei, Zhuang Buqiang
Аннотация
OBJECTIVE: To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy.
METHODS: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed.
RESULTS: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity.
CONCLUSION: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.
METHODS: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed.
RESULTS: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity.
CONCLUSION: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.